Cancers, Vol. 11, Pages 1604: The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models

Conclusions. In summary, RES529, the first dual TORC1/TORC2 dissociative inhibitor, lacking affinity for ABCB1/ABCG2 and having good brain penetration, was active in GBM preclinical/murine models giving credence to its use in clinical trial for patients with GBM treated in association with anti-angiogenetic compounds.

Source: Cancers - October 20, 2019 Category: Cancer & Oncology Authors: Giovanni Luca Gravina Andrea Mancini Alessandro Colapietro Simona Delle Monache Roberta Sferra Simona Pompili Flora Vitale Stefano Martellucci Francesco Marampon Vincenzo Mattei Leda Biordi David Sherris Claudio Festuccia Tags: Article Source Type: research